Rhythm Biosciences Limited (ASX:RHY)

Market Cap	25.85M
Revenue (ttm)	3.33M
Net Income (ttm)	-3.83M
Shares Out	284.08M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	668,954
Average Volume	1,509,937
Open	0.0990
Previous Close	0.0960
Day's Range	0.0900 - 0.0990
52-Week Range	0.0470 - 0.2100
Beta	2.06
RSI	48.84
Earnings Date	Aug 29, 2025

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In 2025, Rhythm Biosciences's revenue was 3.33 million, an increase of 96.80% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.